IN THE CLAIMS:

Claims 1-38 (cancelled).

Claim 39 (currently amended): A compound of the formula II:

(II)
$$R^{2a} \xrightarrow{H} Zb \\ N \xrightarrow{N} H$$

wherein:

ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which moiety may be saturated or unsaturated, which may be aromatic or non-aromatic, and which-optionally may contain contains 1-3 heteroatoms selected independently from O, N and S;

Zb is -O- or -S-;

n is an integer from 0 to 5;

R² represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C₁₋₃alkyl, C₁₋₃alkoxy, C₁₋₃alkylsulphanyl, -NR³R⁴ (wherein R³ and R⁴, which may be the same or different, each represents hydrogen or C₁₋₃alkyl),

or R² represents a group R⁵X¹-, wherein X¹ represents a direct bond, -O-, -CH₂-, -OC(O)-, -C(O)-, -S-, -SO-, -SO₂-, -NR⁶C(O)-, -C(O)NR⁷-, -SO₂NR⁸-, -NR⁹SO₂- or -NR¹⁰- (wherein R⁶, R⁷, R⁸, R⁹ and R¹⁰ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl), and R⁵ is selected from one of the following twenty-two groups:

- 1) hydrogen, oxiranylC₁₋₄alkyl or C₁₋₅alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, chloro, bromo and amino;
- 2) C₁₋₅alkylX²C(O)R¹¹ (wherein X² represents -O- or -NR¹²- (in which R¹² represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R¹¹ represents C₁₋₃alkyl, -NR¹³R¹⁴ or

Application No.: 09/913,020

age 3

-OR¹⁵ (wherein R¹³, R¹⁴ and R¹⁵ which may be the same or different each represents hydrogen, C_{1-5} alkyl or C_{1-3} alkoxy C_{2-3} alkyl));

- 3) C₁₋₅alkylX³R¹⁶ (wherein X³ represents -O-, -S-, -SO-, -SO₂-, -OC(O)-, -NR¹⁷C(O)-, -C(O)NR¹⁸-, -SO₂NR¹⁹-, -NR²⁰SO₂- or -NR²¹- (wherein R¹⁷, R¹⁸, R¹⁹, R²⁰ and R²¹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R¹⁶ represents hydrogen, C₁₋₃alkyl, cyclopentyl, cyclohexyl or a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₄alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy and a group -(-O-)₁(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl));
- 4) C_{1-5} alkyl X^4C_{1-5} alkyl X^5R^{22} (wherein X^4 and X^5 which may be the same or different are each -O-, -S-, -SO-, -SO₂-, -NR²³C(O)-, -C(O)NR²⁴-, -SO₂NR²⁵-, -NR²⁶SO₂- or -NR²⁷- (wherein R²³, R²⁴, R²⁵, R²⁶ and R²⁷ each independently represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl) and R^{22} represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl);
- 5) R²⁸ (wherein R²⁸ is a 4-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkyl, c₁₋₄alkylaminoC₁₋₄alkyl)aminoC₁₋₄alkoxy and a group -(-O-)_f(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered

Application No.: 09/913,020

Page 4

saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl));

- 6) C₁₋₅alkylR²⁸ (wherein R²⁸ is as defined herein);
- 7) C₂₋₅alkenylR²⁸ (wherein R²⁸ is as defined herein);
- 8) C₂₋₅alkynylR²⁸ (wherein R²⁸ is as defined herein);
- 9) R²⁹ (wherein R²⁹ represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from hydroxy, halogeno, amino, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄hydroxyalkyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, C₁₋₄hydroxyalkoxy, carboxy, trifluoromethyl, cyano, -C(O)NR³⁰R³¹, -NR³²C(O)R³³ (wherein R³⁰, R³¹, R³² and R³³, which may be the same or different, each represents hydrogen, C₁₋₄alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and a group -(-O-)_f(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl));
- 10) C₁₋₅alkylR²⁹ (wherein R²⁹ is as defined herein);
- 11) C₂₋₅alkenylR²⁹ (wherein R²⁹ is as defined herein);
- 12) C₂₋₅alkynylR²⁹ (wherein R²⁹ is as defined herein);
- 13) C₁₋₅alkylX⁶R²⁹ (wherein X⁶ represents -O-, -S-, -SO-, -SO₂-, -NR³⁴C(O)-, -C(O)NR³⁵-, -SO₂NR³⁶-, -NR³⁷SO₂- or -NR³⁸- (wherein R³⁴, R³⁵, R³⁶, R³⁷ and R³⁸ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²⁹ is as defined herein):
- 14) C₂₋₅alkenylX⁷R²⁹ (wherein X⁷ represents -O-, -S-, -SO-, -SO₂-, -NR³⁹C(O)-, -C(O)NR⁴⁰-, -SO₂NR⁴¹-, -NR⁴²SO₂- or -NR⁴³- (wherein R³⁹, R⁴⁰, R⁴¹, R⁴² and R⁴³ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²⁹ is as defined herein);
- 15) C_{2-5} alkynyl X^8R^{29} (wherein X^8 represents -O-, -S-, -SO-, -SO₂-, -NR⁴⁴C(O)-, -C(O)NR⁴⁵-, -SO₂NR⁴⁶-, -NR⁴⁷SO₂- or -NR⁴⁸- (wherein R⁴⁴, R⁴⁵, R⁴⁶, R⁴⁷ and R⁴⁸ each

Application No.: 09/913,020

age 5

independently represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl) and R^{29} is as defined herein);

- 16) C₁₋₄alkylX⁹C₁₋₄alkylR²⁹ (wherein X⁹ represents -O-, -S-, -SO-, -SO₂-, -NR⁴⁹C(O)-, -C(O)NR⁵⁰-, -SO₂NR⁵¹-, -NR⁵²SO₂- or -NR⁵³- (wherein R⁴⁹, R⁵⁰, R⁵¹, R⁵² and R⁵³ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R²⁹ is as defined herein);
- 17) C₁₋₄alkylX⁹C₁₋₄alkylR²⁸ (wherein X⁹ and R²⁸ are as defined herein);
- 18) C₂₋₅alkenyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C₁₋₄alkylamino, N,N-di(C₁₋₄alkyl)amino, aminosulphonyl, N-C₁₋₄alkylaminosulphonyl and N,N-di(C₁₋₄alkyl)aminosulphonyl;
- 19) C₂₋₅alkynyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C₁₋₄alkylamino, <u>N,N</u>-di(C₁₋₄alkyl)amino, aminosulphonyl, <u>N</u>-C₁₋₄alkylaminosulphonyl and <u>N,N</u>-di(C₁₋₄alkyl)aminosulphonyl;
- 20) C₂₋₅alkenylX⁹C₁₋₄alkylR²⁸ (wherein X⁹ and R²⁸ are as defined herein);
- 21) C₂₋₅alkynylX⁹C₁₋₄alkylR²⁸ (wherein X⁹ and R²⁸ are as defined herein); and
- 22) C₁₋₄alkylR⁵⁴(C₁₋₄alkyl)_q(X⁹)_rR⁵⁵ (wherein X⁹ is as defined herein, q is 0 or 1, r is 0 or 1, and R⁵⁴ and R⁵⁵ are each independently selected from hydrogen, C₁₋₃alkyl, cyclopentyl, cyclohexyl and a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₄alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄alkoxy, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group -(-O-)₁(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl), with the proviso that R⁵⁴ cannot be hydrogen);

Application No.: 09/913,020

Page 6

and additionally wherein any C_{1-5} alkyl, C_{2-5} alkenyl or C_{2-5} alkynyl group in R^5X^1 - may bear one or more substituents selected from hydroxy, halogeno and amino;

- R¹ represents hydrogen, oxo, halogeno, hydroxy, C₁₋₄alkoxy, C₁₋₄alkyl, C₁₋₄alkoxymethyl, C₁₋₄alkanoyl, C₁₋₄haloalkyl, cyano, amino, C₂₋₅alkenyl, C₂₋₅alkynyl, C₁₋₃alkanoyloxy, nitro, C₁₋₄alkanoylamino, C₁₋₄alkoxycarbonyl, C₁₋₄alkylsulphanyl, C₁₋₄alkylsulphinyl, C₁₋₄alkylsulphonyl, carbamoyl, N-C₁₋₄alkylcarbamoyl, N-C₁₋₄alkylcarbamoyl, N-C₁₋₄alkylsulphonyl, N-C₁₋₄alkylaminosulphonyl, N-C₁₋₄alkylsulphonyl) amino, N-(C₁₋₄alkylsulphonyl)-N-(C₁₋₄alkyl) amino, N-(C₁₋₄alkylsulphonyl) amino, N-(C₁₋₄alkylsulphonyl) amino, N-(C₁₋₄alkylsulphonyl) amino, a C₃₋₇alkylene chain joined to two ring C carbon atoms, C₁₋₄alkanoylaminoC₁₋₄alkyl, carboxy,
- or R¹ represents a group R⁵⁶X¹⁰, wherein X¹⁰ represents a direct bond, -O-, -CH₂-, -OC(O)-, -C(O)-, -S-, -SO-, -SO₂-, -NR⁵⁷C(O)-, -C(O)NR⁵⁸-, -SO₂NR⁵⁹-, -NR⁶⁰SO₂- or -NR⁶¹- (wherein R⁵⁷, R⁵⁸, R⁵⁹, R⁶⁰ and R⁶¹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl), and R⁵⁶ is selected from one of the following twenty-two groups:
 - 1) hydrogen, oxiranylC₁₋₄alkyl or C₁₋₅alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, chloro, bromo and amino;
 - 2) C₁₋₅alkylX¹¹C(O)R⁶² (wherein X¹¹ represents -O- or -NR⁶³- (in which R⁶³ represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁶² represents C₁₋₃alkyl, -NR⁶⁴R⁶⁵ or -OR⁶⁶ (wherein R⁶⁴, R⁶⁵ and R⁶⁶ which may be the same or different each represents hydrogen, C₁₋₅alkyl or C₁₋₃alkoxyC₂₋₃alkyl));
 - 3) C₁₋₅alkylX¹²R⁶⁷ (wherein X¹² represents -O-, -S-, -SO-, -SO₂-, -OC(O)-, -NR⁶⁸C(O)-, -C(O)NR⁶⁹-, -SO₂NR⁷⁰-, -NR⁷¹SO₂- or -NR⁷²- (wherein R⁶⁸, R⁶⁹, R⁷⁰, R⁷¹ and R⁷² each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁶⁷ represents hydrogen, C₁₋₃alkyl, cyclopentyl, cyclohexyl or a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₄alkoxy and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl,

Application No.: 09/913,020

Page 7

 C_{1-4} alkylamino, di $(C_{1-4}$ alkyl)amino, C_{1-4} alkylamino C_{1-4} alkyl, di $(C_{1-4}$ alkyl)amino C_{1-4} alkyl, C_{1-4} alkylamino C_{1-4} alkoxy, di $(C_{1-4}$ alkyl)amino C_{1-4} alkoxy and a group -(-O-)_f $(C_{1-4}$ alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C_{1-4} alkyl));

- 4) C_{1-5} alkyl $X^{13}C_{1-5}$ alkyl $X^{14}R^{73}$ (wherein X^{13} and X^{14} which may be the same or different are each -O-, -S-, -SO-, -SO₂-, -NR⁷⁴C(O)-, -C(O)NR⁷⁵-, -SO₂NR⁷⁶-, -NR⁷⁷SO₂- or -NR⁷⁸- (wherein R⁷⁴, R⁷⁵, R⁷⁶, R⁷⁷ and R⁷⁸ each independently represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl) and R⁷³ represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl);
- 5) R⁷⁹ (wherein R⁷⁹ is a 4-6-membered saturated heterocyclic group (linked via carbon or nitrogen) with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkoxy, di(C₁₋₄alkyl)aminoC₁₋₄alkoxy and a group -(-O-)f(C₁₋₄alkyl)gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl));
- 6) C₁₋₅alkylR⁷⁹ (wherein R⁷⁹ is as defined herein);
- 7) C₂₋₅alkenylR⁷⁹ (wherein R⁷⁹ is as defined herein);
- 8) C₂₋₅alkynylR⁷⁹ (wherein R⁷⁹ is as defined herein);
- 9) R⁸⁰ (wherein R⁸⁰ represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group (linked via carbon or nitrogen) with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from hydroxy, halogeno, amino, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄hydroxyalkyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, C₁₋₄hydroxyalkoxy, carboxy, trifluoromethyl, cyano, -C(O)NR⁸¹R⁸², -NR⁸³C(O)R⁸⁴ (wherein R⁸¹, R⁸², R⁸³

Application No.: 09/913,020

Page 8

and R^{84} , which may be the same or different, each represents hydrogen, C_{1-4} alkyl or C_{1-3} alkoxy C_{2-3} alkyl) and a group -(-O-)_f(C_{1-4} alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C_{1-4} alkyl));

- 10) C₁₋₅alkylR⁸⁰ (wherein R⁸⁰ is as defined herein);
- 11) C₂₋₅alkenylR⁸⁰ (wherein R⁸⁰ is as defined herein);
- 12) C₂₋₅alkynylR⁸⁰ (wherein R⁸⁰ is as defined herein);
- 13) C₁₋₅alkylX¹⁵R⁸⁰ (wherein X¹⁵ represents -O-, -S-, -SO-, -SO₂-, -NR⁸⁵C(O)-, -C(O)NR⁸⁶-, -SO₂NR⁸⁷-, -NR⁸⁸SO₂- or -NR⁸⁹- (wherein R⁸⁵, R⁸⁶, R⁸⁷, R⁸⁸ and R⁸⁹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁸⁰ is as defined herein);
- 14) C₂₋₅alkenylX¹⁶R⁸⁰ (wherein X¹⁶ represents -O-, -S-, -SO-, -SO₂-, -NR⁹⁰C(O)-, -C(O)NR⁹¹-, -SO₂NR⁹²-, -NR⁹³SO₂- or -NR⁹⁴- (wherein R⁹⁰, R⁹¹, R⁹², R⁹³ and R⁹⁴ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁸⁰ is as defined herein);
- 15) C₂₋₅alkynylX¹⁷R⁸⁰ (wherein X¹⁷ represents -O-, -S-, -SO-, -SO₂-, -NR⁹⁵C(O)-, -C(O)NR⁹⁶-, -SO₂NR⁹⁷-, -NR⁹⁸SO₂- or -NR⁹⁹- (wherein R⁹⁵, R⁹⁶, R⁹⁷, R⁹⁸ and R⁹⁹ each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl) and R⁸⁰ is as defined herein);
- 16) C_{1-4} alkyl $X^{18}C_{1-4}$ alkyl R^{80} (wherein X^{18} represents -O-, -S-, -SO-, -SO₂-, -NR¹⁰⁰C(O)-, -C(O)NR¹⁰¹-, -SO₂NR¹⁰²-, -NR¹⁰³SO₂- or -NR¹⁰⁴- (wherein R¹⁰⁰, R¹⁰¹, R¹⁰², R¹⁰³ and R¹⁰⁴ each independently represents hydrogen, C_{1-3} alkyl or C_{1-3} alkoxy C_{2-3} alkyl) and R^{80} is as defined herein);
- 17) C₁₋₄alkylX¹⁸C₁₋₄alkylR⁷⁹ (wherein X¹⁸ and R⁷⁹ are as defined herein);
- 18) C₂₋₅alkenyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C₁₋₄alkylamino, N,N-di(C₁₋₄alkyl)amino, aminosulphonyl, N-C₁₋₄alkylaminosulphonyl and N,N-di(C₁₋₄alkyl)aminosulphonyl;

(1

Application No.: 09/913,020

Page 9

19) C₂₋₅alkynyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, fluoro, amino, C₁₋₄alkylamino, N-di(C₁₋₄alkyl)amino, aminosulphonyl, N-C₁₋₄alkylaminosulphonyl and N-N-di(C₁₋₄alkyl)aminosulphonyl;

- 20) C₂₋₅alkenylX¹⁸C₁₋₄alkylR⁷⁹ (wherein X¹⁸ and R⁷⁹ are as defined herein);
- 21) C_{2-5} alkynyl $X^{18}C_{1-4}$ alkyl R^{79} (wherein X^{18} and R^{79} are as defined herein); and
- 22) $C_{1-4}alkylR^{105}(C_{1-4}alkyl)_x(X^{18})_yR^{106}$ (wherein X^{18} is as defined herein, x is 0 or 1, y is 0 or 1, and R^{105} and R^{106} are each independently selected from hydrogen, $C_{1-3}alkyl$, cyclopentyl, cyclohexyl and a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which $C_{1-3}alkyl$ group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and $C_{1-4}alkoxy$ and which cyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C_{1-4} cyanoalkyl, C_{1-4} alkyl, C_{1-4} hydroxyalkyl, C_{1-4} alkoxy, C_{1-4} alkoxy C_{1-4} alkyl, C_{1-4} alkylsulphonyl C_{1-4} alkyl, C_{1-4} alkoxycarbonyl, C_{1-4} alminoalkyl, C_{1-4} alkylamino, di(C_{1-4} alkyl)amino C_{1-4} alkylamino C_{1-4} alkyl, di(C_{1-4} alkyl)amino C_{1-4} alkyl, C_{1-4} alkylamino C_{1-4} alkoxy and a group C_{1-4} alkylamino C_{1-4} alkoxy, di(C_{1-4} alkyl)amino C_{1-4} alkoxy and a group C_{1-4} alkyl)gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C_{1-4} alkyl) with the proviso that C_{1-4} alkylogen);

and additionally wherein any C_{1-5} alkyl, C_{2-5} alkenyl or C_{2-5} alkynyl group in $R^{56}X^{10}$ - may bear one or more substituents selected from hydroxy, halogeno and amino;

R^{2a} represents hydrogen, halogeno, C₁₋₃alkyl, trifluoromethyl, C₁₋₃alkoxy, C₁₋₃alkylsulphanyl, -NR^{3a}R^{4a} (wherein R^{3a} and R^{4a}, which may be the same or different, each represents hydrogen or C₁₋₃alkyl), or R^{5a}(CH₂)_{za}X^{1a} (wherein R^{5a} is a 4-, 5- or 6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₄cyanoalkyl, C₁₋₄alkyl, C₁₋₄hydroxyalkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl, C₁₋₄alkoxycarbonyl, C₁₋₄aminoalkyl, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkyl, C₁₋₄alkylaminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl,

Application No.: 09/913,020

Page 10

-(-O-)_f(C₁₋₄alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 4-6-membered saturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from C₁₋₄alkyl), za is an integer from 0 to 4 and X^{1a} represents a direct bond, -O-, -CH₂-, -S-, -SO-, -SO₂-, -NR^{6a}C(O)-, -C(O)NR^{7a}-, -SO₂NR^{8a}-, -NR^{9a}SO₂- or -NR^{10a}- (wherein R^{6a}, R^{7a}, R^{8a}, R^{9a} and R^{10a} each independently represents hydrogen, C₁₋₃alkyl or C₁₋₃alkoxyC₂₋₃alkyl)); or a salt or prodrug thereof,

with the proviso that R² is not hydrogen, and excluding the compounds:

- 6,7-dimethoxy 4-(1-naphthylsulphanyl)quinazoline,
- 6,7 dimethoxy 4 (2 naphthylsulphanyl)quinazoline,
- 6.7 dimethoxy 4 (1-naphthyloxy)quinazoline and
- 6,7 dimethoxy 4 (2-naphthyloxy)quinazoline.

Claim 40 (previously added): A compound of the formula II according to claim 39 wherein R^2 represents hydroxy, halogeno, cyano, nitro, trifluoromethyl, C_{1-3} alkyl, amino or R^5X^1 -, wherein X^1 is as defined in claim 39 and R^5 is selected from one of the following twenty-two groups:

- 1) C₁₋₄alkyl which may be unsubstituted or which may be substituted with one or more groups selected from fluoro, chloro and bromo, or C₂₋₅alkyl which may be unsubstituted or substituted with one or more groups selected from hydroxy and amino;
- 2) C₂₋₃alkylX²C(O)R¹¹ (wherein X² is as defined in claim 39 and R¹¹ represents -NR¹³R¹⁴ or -OR¹⁵ (wherein R¹³, R¹⁴ and R¹⁵ which may be the same or different are each C₁₋₄alkyl or C₁₋₂alkoxyethyl));
- 3) C₂₋₄alkylX³R¹⁶ (wherein X³ is as defined in claim 39 and R¹⁶ is a group selected from C₁₋₃alkyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl and tetrahydropyranyl, which C₁₋₃alkyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno and C₁₋₂alkoxy and which cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl or tetrahydropyranyl group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₃cyanoalkyl, C₁₋₃alkyl, C₁₋₃hydroxyalkyl, C₁₋₃alkoxy,

Application No.: 09/913,020

Page 11

C₁₋₂alkoxyC₁₋₃alkyl, C₁₋₂alkylsulphonylC₁₋₃alkyl, C₁₋₃alkoxycarbonyl, C₁₋₃alkylamino, di(C₁₋₃alkyl)amino, C₁₋₃alkylaminoC₁₋₃alkyl, di(C₁₋₃alkyl)aminoC₁₋₃alkyl, C₁₋₃alkylaminoC₁₋₃alkoxy, di(C₁₋₃alkyl)aminoC₁₋₃alkoxy and a group -(-O-)_f(C₁₋₃alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a heterocyclic group selected from pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl, morpholino and thiomorpholino, which cyclic group may bear one or more substituents selected from C₁₋₃alkyl));

- 4) C₂₋₃alkylX⁴C₂₋₃alkylX⁵R²² (wherein X⁴ and X⁵ are as defined in claim 39 and R²² represents hydrogen or C₁₋₃alkyl);
- 5) R²⁸ (wherein R²⁸ is as defined in claim 39);
- 6) C₁₋₄alkylR¹¹⁰ (wherein R¹¹⁰ is a group selected from pyrrolidinyl, piperazinyl, piperidinyl, imidazolidin-1-yl, azetidinyl, 1,3-dioxolan-2-yl, 1,3-dioxan-2-yl, 1,3-dithiolan-2-yl and 1,3-dithian-2-yl, which group is linked to C₁₋₄alkyl through a carbon atom and which group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₃cyanoalkyl, C₁₋₃alkyl, C₁₋₃hydroxyalkyl, C₁₋₃alkoxy, C₁₋₂alkoxyC₁₋₃alkyl, C₁₋₂alkylsulphonylC₁₋₃alkyl, C₁₋₃alkoxycarbonyl, C₁₋₃alkylamino, di(C₁₋₃alkyl)amino, C₁₋₃alkylaminoC₁₋₃alkyl, di(C₁₋₃alkyl)aminoC₁₋₃alkyl, C_{1-3} alkylamino C_{1-3} alkoxy, di $(C_{1-3}$ alkyl)amino C_{1-3} alkoxy and a group -(-O-)₆(C₁₋₃alkyl)_oringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a heterocyclic group selected from pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl, morpholino and thiomorpholino, which cyclic group may bear one or more substituents selected from C₁₋₃alkyl)) or C₂₋₄alkylR¹¹¹ (wherein R¹¹¹ is a group selected from morpholino, thiomorpholino, azetidin-1-yl, pyrrolidin-1-yl, piperazin-1-yl and piperidino which group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, cyano, C₁₋₃cyanoalkyl, C₁₋₃alkyl, C₁₋₃hydroxyalkyl, C₁₋₃alkoxy, C₁₋₂alkoxyC₁₋₃alkyl, C₁₋₂alkylsulphonylC₁₋₃alkyl, C₁₋₃alkoxycarbonyl, C₁₋₃alkylamino, di(C₁₋₃alkyl)amino, C₁₋₃alkylaminoC₁₋₃alkyl, di(C₁₋₃alkyl)aminoC₁₋₃alkyl, C_{1-3} alkylamino C_{1-3} alkoxy, di $(C_{1-3}$ alkyl)amino C_{1-3} alkoxy and a group -(-O-)_f(C₁₋₃alkyl)_gringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a heterocyclic group selected from pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl, azetidinyl,

01

Application No.: 09/913,020

Page 12

morpholino and thiomorpholino, which cyclic group may bear one or more substituents selected from C_{1-3} alkyl));

- 7) C₃₋₄alkenylR¹¹² (wherein R¹¹² represents R¹¹⁰ or R¹¹¹ as defined herein);
- 8) C₃₋₄alkynylR¹¹² (wherein R¹¹² represents R¹¹⁰ or R¹¹¹ as defined herein);
- 9) R²⁹ (wherein R²⁹ is as defined in claim 39);
- 10) C₁₋₄alkylR²⁹ (wherein R²⁹ is as defined in claim 39);
- 11) 1-R²⁹prop-1-en-3-yl or 1-R²⁹but-2-en-4-yl (wherein R²⁹ is as defined in claim 39 with the proviso that when R⁵ is 1-R²⁹prop-1-en-3-yl, R²⁹ is linked to the alkenyl group via a carbon atom);
- 12) 1-R²⁹prop-1-yn-3-yl or 1-R²⁹but-2-yn-4-yl (wherein R²⁹ is as defined in claim 39 with the proviso that when R⁵ is 1-R²⁹prop-1-yn-3-yl, R²⁹ is linked to the alkynyl group via a carbon atom);
- 13) C₁₋₅alkylX⁶R²⁹ (wherein X⁶ and R²⁹ are as defined in claim 39);
- 14) 1- $(R^{29}X^7)$ but-2-en-4-yl (wherein X^7 and R^{29} are as defined in claim 39);
- 15) 1-(R²⁹X⁸)but-2-yn-4-yl (wherein X⁸ and R²⁹ are as defined in claim 39);
- 16) C₂₋₃alkylX⁹C₁₋₃alkylR²⁹ (wherein X⁹ and R²⁹ are as defined in claim 39);
- 17) C₂₋₃alkylX⁹C₁₋₃alkylR²⁸ (wherein X⁹ and R²⁸ are as defined in claim 39);
- 18) C_{2-5} alkenyl which may be unsubstituted or which may be substituted with one or more fluorine atoms or with one or two groups selected from hydroxy, fluoro, amino, C_{1-4} alkylamino, N_{1-4} di(C_{1-4} alkyl)amino, aminosulphonyl, N_{1-4} di(N_{1-4} alkyl)aminosulphonyl;
- 19) C₂₋₅alkynyl which may be unsubstituted or which may be substituted with one or more fluorine atoms or with one or two groups selected from hydroxy, fluoro, amino, C₁₋₄alkylamino, N,N-di(C₁₋₄alkyl)amino, aminosulphonyl, N-C₁₋₄alkylaminosulphonyl and N,N-di(C₁₋₄alkyl)aminosulphonyl;
- 20) C₂₋₄alkenylX⁹C₁₋₃alkylR²⁸ (wherein X⁹ and R²⁸ are as defined in claim 39);
- 21) C₂₋₄alkynylX⁹C₁₋₃alkylR²⁸ (wherein X⁹ and R²⁸ are as defined in claim 39); and
- 22) C_{1-3} alkyl R^{54} (C_{1-3} alkyl) $_q(X^9)_rR^{55}$ (wherein X^9 , q, r, R^{54} and R^{55} are as defined in claim 39);

CI

Application No.: 09/913,020

Page 13

and additionally wherein any C_{1-5} alkyl, C_{2-5} alkenyl or C_{2-5} alkynyl group in R^5X^1 - may bear one or more substituents selected from hydroxy, halogeno and amino.

Claim 41 (previously added): A compound according to claim 39 wherein Zb is -O-.

Claim 42 (previously added): A compound according to claim 39 wherein ring C is a 9-10-membered heteroaromatic bicyclic moiety which contains 1-3 heteroatoms selected independently from O, N and S.

Claim 43 (previously added): A compound according to claim 39 wherein R¹ represents oxo, halogeno, hydroxy, C₁₋₂alkoxy, C₁₋₂alkyl, C₁₋₂alkoxymethyl, C₂₋₃alkanoyl, C₁₋₂haloalkyl, cyano, amino, C₂₋₄alkenyl, C₂₋₄alkynyl, C₂₋₃alkanoyloxy, nitro, C₂₋₃alkanoylamino, C₁₋₂alkoxycarbonyl, C₁₋₂alkylsulphanyl, C₁₋₂alkylsulphinyl, C₁₋₂alkylsulphonyl, carbamoyl, N-C₁₋₂alkylcarbamoyl, N-C₁₋₂alkylsulphonyl, aminosulphonyl, N-C₁₋₂alkylaminosulphonyl, N-C₁₋₂alkylsulphonyl, N-C₁₋₂alkylsulphonyl) amino, N-(C₁₋₂alkylsulphonyl)-N-(C₁₋₂alkylsulphonyl) amino or a C₃₋₇alkylene chain joined to two ring C carbon atoms.

Claim 44 (previously added): A compound according to claim 39 wherein n is 0, 1 or 2.

Claim 45 (previously added): A compound according to claim 39 wherein Zb is -O-, with the proviso that R^2 is not hydrogen, substituted or unsubstituted C_{1-5} alkyl, halogeno, C_{1-5} alkoxy, C_{2-5} alkenyl, phenoxy or phenyl C_{1-5} alkoxy.

Claim 46 (currently amended): A compound according to claim 39 selected from 6-methoxy-7 ((1-methylpiperidin-4-yl)methoxy) 4 (2-naphthyloxy)quinazoline, 6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)-4-(quinolin-7-yloxy)quinazoline, 7-(3-(1,1-dioxothiomorpholino)propoxy)-6-methoxy-4-(quinolin-7-yloxy)quinazoline, 6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)-4-(quinolin-7-yloxy)quinazoline,

Application No.: 09/913,020

Page 14

6-methoxy-7-((1-methylpiperidin-3-yl)methoxy)-4-(quinolin-7-yloxy)quinazoline,

4-(4-chloroquinolin-7-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,

6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)-4-(4-methylquinolin-7-yloxy) quinazoline,

6-methoxy-4-(4-methylquinolin-7-yloxy)-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,

6-methoxy-7-(2-(2-methoxyethoxy)ethoxy)-4-(quinolin-7-yloxy)quinazoline,

6-methoxy-7-((1-(2-methylsulphonylethyl)piperidin-4-yl)methoxy)-4-(quinolin-7-yloxy)quin azoline,

4-(2,3-dimethylindol-5-yloxy)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy) quinazoline,

4-(2,3-dimethylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline,

6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)-4-(2-trifluoromethylindol-5-yloxy) quinazoline,

6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)-4-(2-trifluoromethylindol-5-yloxy)quinazoline,

(R,S)-4-(3-fluoroquinolin-7-yloxy)-6-methoxy-7-((1-methylpiperidin-3-yl)methoxy) quinazoline,

4-(indol-5-yloxy)-6-methoxy-7-(3-methylsulphonylpropoxy)quinazoline,

7-(3-N,N-dimethylaminopropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(2-morpholinoethoxy)ethoxy)quinazoline,

7-(2-(N.N-diethylamino)ethoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,

6-methoxy-7-(3-piperidinopropoxy)-4-(quinolin-7-yloxy)quinazoline,

4-(2-methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline,

4-(2-methylindol-5-yloxy)-7-(2-(piperidin-1-yl)ethoxy)quinazoline,

4-(2-methylindol-5-yloxy)-7-(2-(1H-1,2,4-triazol-1-yl)ethoxy)quinazoline,

6-methoxy-7-(3-piperidinopropoxy)-4-(6-trifluoromethylindol-5-yloxy)quinazoline,

7-(3-(methylsulphonyl)propoxy)-4-(2-methylindol-5-yloxy)quinazoline,

7-(3-(N,N-dimethylamino)propoxy)-4-(2,3-dimethylindol-5-yloxy)-6-methoxy-quinazoline,

4-(2.3-dimethylindol-5-yloxy)-6-methoxy-7-(1-methylpiperidin-3-ylmethoxy) quinazoline,

7-(2-(N,N-diethylamino)ethoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,

4-(indol-5-yloxy)-6-methoxy-7-(2-(piperidin-2-yl)ethoxy)quinazoline,

4-(indol-5-yloxy)-6-methoxy-7-(2-(piperidin-1-yl)ethoxy)quinazoline,

4-(indol-6-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,

Application No.: 09/913,020

Page 15

7-(3-(ethylsulphonyl)propoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,

6-methoxy-4-(3-methylindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline,

7-(2-hydroxy-3-piperidinopropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,

7-(2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy)-6-methoxy-4-(2-methylpindol-5-yloxy)quin azoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(N-methylamino)ethoxy)quinazoline, and

7-(2-hydroxy-3-(isopropylamino)propoxy)-6-methoxy-4-(2-methylindol-5-yloxy) quinazoline,

or a salt thereof.

01

Claim 47 (previously added): A compound according to claim 39 selected from

6-methoxy-7-(3-morpholinopropoxy)-4-(quinolin-7-yloxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-((1-methylpiperidin-4-yl)methoxy)quinazoline,

4-(indol-5-yloxy)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,

4-(indol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(3-methylsulphonylpropoxy)quinazoline,

7-((1-cyanomethyl)piperidin-4-ylmethoxy)-6-methoxy-4-(2-methylindol-5-yloxy) quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-morpholinoethoxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-pyrrolidin-1-ylethoxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(1-methylpiperidin-3-ylmethoxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-piperidinoethoxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(2- $(\underline{N}$ -methyl- \underline{N} -(4-pyridyl)amino)ethoxy) quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(3-morpholinopropoxy)quinazoline,

6-methoxy-7-(2-(2-methoxyethoxy)ethoxy)-4-(2-methylindol-5-yloxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(1H-1,2,4-triazol-1-yl)ethoxy)quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(2-(4-methylpiperazin-1-yl)ethoxy)ethoxy) quinazoline,

6-methoxy-4-(2-methylindol-5-yloxy)-7-(3-piperidinopropoxy)quinazoline,

Application No.: 09/913,020

Page 16

- 4-(indol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,
- 6-methoxy-7-(1-(2-methoxyethyl)piperidin-4-ylmethoxy)-4-(2-methylindol-5-yloxy) quinazoline,
- 6-methoxy-4-(2-methylindol-5-yloxy)-7-((2-(2-pyrrolidin-1-ylethyl)carbamoyl)vinyl) quinazoline,
- 6-methoxy-4-(2-methylindol-5-yloxy)-7-(3-(4-methypiperazin-1-yl)propoxy)quinazoline,
- 6-methoxy-4-(2-methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline,
- 6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(piperidin-4-yloxy)ethoxy)quinazoline,
- 6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(N-methyl-N-methylsulphonylamino)ethoxy)qui nazoline,
- 7-(2-(1-(2-cyanoethyl)piperidin-4-yloxy)ethoxy)-6-methoxy-4-(2-methylindol-5-yloxy) quinazoline,
- 4-(2-methylindol-5-yloxy)-7-(3-(pyrrolidin-yl)propoxy)quinazoline,
- 4-(2-methylindol-5-yloxy)-7-(3-(1,1-dioxothiomorpholino)propoxy)quinazoline,
- 4-(2-methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline,
- 4-(indol-5-yloxy)-6-methoxy-7-(2-(2-methoxyethoxy)ethoxy)quinazoline,
- 7-(3-(N,N-dimethylamino)propoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,
- 7-(3-(N,N-diethylamino)propoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,
- 7-(3-(1,1-dioxothiomorpholino)propoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,
- 4-(indol-5-yloxy)-6-methoxy-7-(2-(4-pyridyloxy)ethoxy)quinazoline,
- 4-(indol-6-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,
- 7-(1-(2-methoxyethyl)piperidin-4-ylmethoxy)-4-(2-methylindol-5-yloxy)quinazoline,
- 7-(2-hydroxy-3-morpholinopropoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,
- 7-(2-(1-(2-methoxyethyl)piperidin-4-yl)ethoxy)-6-methoxy-4-(2-methylindol-5-yloxy) quinazoline,
- 7-(2-hydroxy-3-pyrrolidin-1-ylpropoxy)-6-methoxy-4-(2-methylindol-5-yloxy) quinazoline,
- 7-(3-(N,N-diethylamino)-2-hydroxypropoxy)-6-methoxy-4-(2-methylindol-5-yloxy) quinazoline,
- 7-(3-(1,1-dioxothiomorpholino)propoxy)-6-methoxy-4-(2-methylindol-5-yloxy) quinazoline, 6-methoxy-4-(2-methylindol-5-yloxy)-7-(2-(4-pyridyloxy)ethoxy)quinazoline,

Application No.: 09/913,020

Page 17

- 4-(indol-5-yloxy)-6-methoxy-7-(3-morpholinopropoxy)quinazoline,
- (2R)-6-methoxy-(2-methyl-1H-indol-5-yloxy)-7-(2-hydroxy-3-piperidinopropoxy) quinazoline,
- (5R)-6-methoxy-4-(2-methyl-1H-indol-5-yloxy)-7-(2-oxopyrrolidin-5-ylmethoxy) quinazoline,
- 4-(4-bromoindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,
- 6-methoxy-4-(2-methylindol-5-yloxy)-7-(1-(2-(pyrrolidin-1-yl)ethyl)-piperidin-4-ylmethoxy)quinazoline,
- (2R)-7-(2-hydroxy-3-(pyrrolidin-1-yl)propoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,
- (2R)-7-(2-hydroxy-3-morpholinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,
- (2R)-7-(2-hydroxy-3-piperidinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,
- (2S)-7-(2-hydroxy-3-((N,N-diisopropyl)amino)propoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,
- (2S)-7-(2-hydroxy-3-piperidinopropoxy)-4-(indol-5-yloxy)-6-methoxyquinazoline,
- (2R)-7-(2-hydroxy-3-piperidinopropoxy)-6-methoxy-4-(3-methylindol-5-yloxy) quinazoline,
- (2R)-7-(2-hydroxy-3-(pyrrolidin-1-yl)propoxy)-6-methoxy-4-(3-methylindol-5-yloxy) quinazoline,
- (2R)-7-(2-hydroxy-3-(pyrrolidin-1-yl)propoxy)-6-methoxy-4-(2-methylindol-5-yloxy)quinaz oline,
- (2R)-7-(2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy)6-methoxy-4-(2-methylindol-5-yloxy)quinazoline,
- 6-methoxy-4-(2-methylindol-5-yloxy)-7-(1-(2-morpholinoethyl)piperidin-4-ylmethoxy) quinazoline,
- 4-(3-fluoro-quinolin-7-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,
- 4-(3-fluoro-quinolin-7-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,
- 6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)-4-(1*H*-pyrrolo[2,3-*b*]pyridin-5-yloxy) quinazoline,
- (2S)-6-methoxy-(2-methyl-1*H*-indol-5-yloxy)-7-(2-hydroxy-3-piperidinopropoxy) quinazoline, and
- 4-(6-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy) quinazoline,

or a salt thereof.

Claim 48 (previously added): A compound according to claim 39 selected from 6-methoxy-4-(2-methylindol-5-yloxy)-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,

4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline,

4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazoline,

4-(6-fluoroindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,

4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline,

4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,

4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy) quinazoline,

4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-piperidinopropoxy)quinazoline,

4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy) quinazoline,

4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy) quinazoline,

4-(4-fluoroindol-5-yloxy)-6-methoxy-7-(2-(1-methylpiperidin-4-yl)ethoxy)quinazoline,

(2R)-7-(2-hydroxy-3-(pyrrolidin-1-yl)propoxy)-4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxyquinazoline, and

4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(2-(1-methylpiperidin-4-yl)ethoxy) quinazoline,

or a salt thereof.

Claim 49 (previously added): A compound according to claim 39 in the form of a pharmaceutically acceptable salt.

Claim 50 (cancelled).

Claims 51 (previously added): A pharmaceutical composition which comprises as active ingredient a compound of formula I or a pharmaceutically acceptable salt thereof according to claim 39 in association with a pharmaceutically acceptable excipient or carrier.

 $\cap I$

Application No.: 09/913,020

Page 19

Claims 52-60 (cancelled).

Claim 61 (new): A compound according to claim 39 wherein ring C is selected from indolyl and quinolinyl.

Claim 62 (new): A method for producing an antiangiogenic or vascular permeability reducing effect in a warm-blooded animal in need thereof, said method comprising administering to said animal an effective amount of a compound of the formula II according to claim 39.